DiaMedica Therapeutics Inc. Common Stock/$DMAC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
- Ticker
- $DMAC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 35
- Headquarters
- Minneapolis, United States
- Website
- www.diamedica.com
DMAC Metrics
BasicAdvanced
$487M
-
-$0.72
0.97
-
Price and volume
Market cap
$487M
Beta
0.97
52-week high
$11.00
52-week low
$5.25
Average daily volume
240K
Financial strength
Current ratio
6.721
Quick ratio
6.635
Long term debt to equity
0.002
Total debt to equity
0.005
Profitability
EBITDA (TTM)
-39.174
Effective tax rate (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-64.12%
Return on equity (TTM)
-114.62%
Valuation
Price to book
12.72
Price to tangible book (TTM)
12.72
Price to free cash flow (TTM)
-15.032
Free cash flow yield (TTM)
-6.65%
Free cash flow per share (TTM)
-0.601
Growth
Earnings per share change (TTM)
3.68%
3-year earnings per share growth (CAGR)
4.84%
10-year earnings per share growth (CAGR)
5.76%
What the Analysts think about DMAC
Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
Analyst projections of the future price of DiaMedica Therapeutics Inc. Common Stock stock.
Bulls say / Bears say
In a small Phase 2 pre-eclampsia cohort, DM199 produced sizeable reductions in maternal blood pressure, with systolic pressure remaining below 160 mmHg over 24 hours. This is an encouraging early clinical signal for the lead programme. (DiaMedica Therapeutics)
DM199 is also being tested in early-onset fetal growth restriction, a condition with no approved drug treatment. The first two trial cohorts are enrolled, and results are due at a November event, creating another near-term data catalyst. (DiaMedica Therapeutics, DiaMedica Therapeutics)
The Phase 2/3 stroke study has passed 85% of the 200-participant threshold for its planned interim analysis, with about 70 sites active. The analysis, expected in early 2027, is a major catalyst for the programme. (DiaMedica Therapeutics)
ReMEDy2 enrolment has been slower than expected, and the interim review may stop the study for futility or lead to a much larger trial of up to 728 participants. Further delays could increase costs and defer a decisive read-out. (U.S. Securities and Exchange Commission)
The pre-eclampsia result comes from a small, open-label, single-centre, single-arm proof-of-concept study, so it cannot establish that DM199 caused the improvement. Larger and more rigorous trials must confirm the apparent benefit. (U.S. Securities and Exchange Commission, DiaMedica Therapeutics)
DiaMedica remains loss-making and used $17.2 million in operating cash in the first half of 2026. Although it expects cash to last through 2027, it says substantial additional funding will be needed to advance development, creating financing and potential dilution risk. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
DMAC Financial Performance
Revenues and expenses
DMAC Earnings Performance
Company profitability
Upcoming events
No upcoming events
DMAC News
AllArticlesVideos
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
Business Wire1 day ago
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
Business Wire1 month ago
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
Business Wire2 months ago
Funds containing DMAC
Fund name | Fund size | $DMAC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.